JAK inhibitors in the treatment of atopic dermatitis
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense patient burden. Safe, targeted treatment options are currently limited. We conducted a focused review of the published literature, including clinical trial results, case reports, and abstracts, as well as presentations from scientific meetings and data from industry press releases, to describe the use of topical and systemic janus kinase (JAK) inhibitors (JAKi) in the treatment AD. New topical JAKi include ruxolitinib (JAK1/2) and delgocitinib (pan-JAK). Ruxolitinib cream met all primary and secondary endpoints in phase 3 clinical trials for mild-to-moderate AD with minimal treatment-emergent adverse events (TEAEs). Delgocitinib ointment was recently approved in Japan for pediatric and adult AD. Oral JAKi include baricitinib (JAK1/2), abrocitinib (JAK1-selective), and upadacitinib (JAK1-selective). All three met primary and secondary endpoints across numerous trials for moderate-to-severe AD. TEAEs were mainly mild-to-moderate and included acne, nausea, headache, upper respiratory tract infection, and to a lesser degree, herpes infection and selected laboratory abnormalities. JAKi hold great promise as the next generation of targeted AD therapy. While their outstanding efficacy is balanced by a favorable safety profile in clinical trials, real-world data are needed to better understand long-term safety, durability, and treatment success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“44 45-46 Although having a lower reported efficacy compared with the other two oral JAK inhibitors in phase 3 studies for atopic dermatitis, baricitinib was the first JAK inhibitor approved for eczema in Europe, in September 2020.”
BackgroundEndogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Patient burden and quality of life in atopic dermatitis in US adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Simpson, E. L., Ong, P. Y., & Chiesa Fuxench, Z. C. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.07.006 · Cited by 648
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Atopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Self-citationPaller, A. S., Tom, W. L., Lebwohl, M. G., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.046 · Cited by 577
Self-citationJAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Simpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M. J., Beck, L. A., Guttman-Yassky, E., Pariser, D., Blauvelt, A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3336 · Cited by 524
Self-citationSimpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30732-7 · Cited by 522
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., Kataoka, Y., Chu, C.-Y., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 476
Comorbidities and the impact of atopic dermatitis
Silverberg, J. I. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.04.020 · Cited by 431
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Chiesa Fuxench, Z. C., Block, J. K., Boguniewicz, M., Boyle, J., Fonacier, L., Gelfand, J. M., Grayson, M. H., Margolis, D. J., Mitchell, L., Silverberg, J. I., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.08.028 · Cited by 419
Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1406 · Cited by 404
Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.054 · Cited by 399
Self-citationSimpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18898 · Cited by 396
Self-citationYosipovitch, G., Reaney, M., Mastey, V., Eckert, L., Abbé, A., Nelson, L., Clark, M., Williams, N., Chen, Z., Ardeleanu, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17744 · Cited by 394
Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis
Reitamo, S. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.8.999 · Cited by 378
Guttman-Yassky, E., Thaçi, D., Pangan, A. L., Hong, H. C.-H., Papp, K. A., Reich, K., Beck, L. A., Mohamed, M.-E. F., Othman, A. A., Anderson, J. K., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.025 · Cited by 369
Itch: From mechanism to (novel) therapeutic approaches
Yosipovitch, G., Rosen, J. D., & Hashimoto, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.005 · Cited by 343
New Insights into Atopic Dermatitis: Role of Skin Barrier and Immune Dysregulation
Leung, D. Y. M. (2013) · Allergology International · doi:10.2332/allergolint.13-rai-0564 · Cited by 331
Bao, L., Zhang, H., & Chan, L. S. (2013) · JAK-STAT · doi:10.4161/jkst.24137 · Cited by 320
Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317
Papp, K., Szepietowski, J. C., Kircik, L., Toth, D., Eichenfield, L. F., Leung, D. Y. M., Forman, S. B., Venturanza, M. E., Sun, K., Kuligowski, M. E., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.085 · Cited by 313
Silverberg, J. I., & Simpson, E. L. (2013) · Pediatric Allergy and Immunology · doi:10.1111/pai.12095 · Cited by 310
Yew, Y. W., Thyssen, J. P., & Silverberg, J. I. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.09.035 · Cited by 309
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Reich, K., Kabashima, K., Peris, K., Silverberg, J. I., Eichenfield, L. F., Bieber, T., Kaszuba, A., Kolodsick, J., Yang, F. E., Gamalo, M., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3260 · Cited by 285
Associations of Childhood Eczema Severity: A US Population-Based Study
Silverberg, J. I., & Simpson, E. L. (2014) · Dermatitis® · doi:10.1097/der.0000000000000034 · Cited by 264
Czarnowicki, T., Krueger, J. G., & Guttman-Yassky, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.004 · Cited by 260
Gooderham, M. J., Forman, S. B., Bissonnette, R., Beebe, J. S., Zhang, W., Banfield, C., Zhu, L., Papacharalambous, J., Vincent, M. S., & Peeva, E. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.2855 · Cited by 247
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Genetic and epigenetic studies of atopic dermatitis
Bin, L., & Leung, D. Y. M. (2016) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-016-0158-5 · Cited by 242
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226 · cited 1×
“47 This study was conducted in the United States and Canada and evaluated 307 patients aged from 18 to 70 years to compare the effect of topical ruxolitinib at doses of 0.15%, 0.5%, and 1.5%, once or twice daily, with 0.1% triamcinolone and vehicle.”
MethodInfluentialTreatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy, L. L., Urban, J., & King, B. A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.06.045 · Cited by 216
Simpson, E., Bissonnette, R., Eichenfield, L. F., Guttman-Yassky, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T., Reich, K., Kabashima, K., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.104 · Cited by 183
Self-citationBurden of Sleep and Fatigue in US Adults With Atopic Dermatitis
Yu, S. H., Attarian, H., Zee, P., & Silverberg, J. I. (2016) · Dermatitis® · doi:10.1097/der.0000000000000161 · Cited by 175
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Simpson, E. L., Ong, P. Y., & Chiesa Fuxench, Z. C. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.07.042 · Cited by 169
Renert-Yuval, Y., Del Duca, E., Pavel, A. B., Fang, M., Lefferdink, R., Wu, J., Diaz, A., Estrada, Y. D., Canter, T., Zhang, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.001 · Cited by 168
Self-citationBieber, T., Thyssen, J. P., Reich, K., Simpson, E. L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16948 · Cited by 152
Nakagawa, H., Nemoto, O., Igarashi, A., & Nagata, T. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16014 · Cited by 145
Simpson, E. L., Forman, S., Silverberg, J. I., Zirwas, M., Maverakis, E., Han, G., Guttman-Yassky, E., Marnell, D., Bissonnette, R., Waibel, J., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.02.028 · Cited by 140
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Silverberg, J. I., de Bruin-Weller, M. S., Bieber, T. R. M., Soong, W., Kabashima, K., Costanzo, A., Rosmarin, D. M., Lynde, C. W., Liu, J., Gamelli, A., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.036 · Cited by 139
Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17932 · Cited by 130
Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L. S., Grayson, M. H., Fuxench, Z. C. C., Simpson, E. L., & Ong, P. Y. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.05.055 · Cited by 126
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kabashima, K., Oda, M., & Nagata, T. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.014 · Cited by 126
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Czarnowicki, T., He, H., Canter, T., Han, J., Lefferdink, R., Erickson, T., Rangel, S., Kameyama, N., Kim, H. J., Pavel, A. B., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.031 · Cited by 118
Self-citationKim, B., Sun, K., Papp, K. A., Venturanza, M. E., Nasir, A., & Kuligowski, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.009 · Cited by 114
Silverberg, J. I., Simpson, E. L., Wollenberg, A., Bissonnette, R., Kabashima, K., DeLozier, A. M., Sun, L., Cardillo, T. E., Nunes, F. P., & Reich, K. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.1273 · Cited by 114
No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis
Paller, A. S., Fölster‐Holst, R., Chen, S. C., Diepgen, T. L., Elmets, C. A., Margolis, D. J., & Pollock, B. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.075 · Cited by 113
Self-citationPhase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Oda, M., Kabashima, K., & Nagata, T. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.004 · Cited by 108
Worm, M., Bauer, A., Elsner, P., Mahler, V., Molin, S., & Nielsen, T. S. S. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18469 · Cited by 107
Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders
Silverberg, J. I. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.03.008 · Cited by 105
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Murata, R., Kaino, H., & Nagata, T. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15173 · Cited by 105
Schlessinger, J., Shepard, J. S., Gower, R., Su, J. C., Lynde, C. W., Cha, A., Ports, W. C., Purohit, V. S., Takiya, L., Werth, J. L., et al. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00510-6 · Cited by 100
Atopic dermatitis in US adults
Hua, T., & Silverberg, J. I. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.07.019 · Cited by 88
Health Utility Scores of Atopic Dermatitis in US Adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L. S., Grayson, M. H., Ong, P. Y., Fuxench, Z. C. C., & Simpson, E. L. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.11.043 · Cited by 67
Tanimoto, A., Shinozaki, Y., Yamamoto, Y., Katsuda, Y., Taniai‐Riya, E., Toyoda, K., Kakimoto, K., Kimoto, Y., Amano, W., Konishi, N., et al. (2018) · Experimental Dermatology · doi:10.1111/exd.13370 · Cited by 60
Wollenberg, A., Nakahara, T., Maari, C., Peris, K., Lio, P., Augustin, M., Silverberg, J. I., Rueda, M. J., DeLozier, A. M., Pierce, E. J., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17278 · Cited by 54
King, B., Maari, C., Lain, E. L., Silverberg, J. I., Issa, M., Holzwarth, K., Brinker, D. R., Cardillo, T. E., Nunes, F. P., & Simpson, E. L. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00602-x · Cited by 46
Yamamoto, Y., Otsuka, A., Nakashima, C., Ishida, Y., Honda, T., Egawa, G., Amano, W., Usui, K., Hamada, Y., Wada, M., et al. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.12.008 · Cited by 26
Morris, G. M., Nahmias, Z. P., & Kim, B. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.12.016 · Cited by 21
Simpson, E. L., Wollenberg, A., Bissonnette, R., Silverberg, J. I., Papacharalambous, J., Zhu, L., Zhang, W., BEEBE, J. S., Vincent, M. S., Peeva, E., et al. (2021) · Dermatitis · doi:10.1097/der.0000000000000725 · Cited by 21
Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
Peterson, D. M., & Vesely, M. D. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.01.020 · Cited by 18
Atopic dermatitis: Tofacitinib, an option for refractory disease
Ferreira, S. B., Ferreira, R. B., & Scheinberg, M. A. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3325 · Cited by 16
Gooderham, M., Chu, C., Rojo, R., Valdez, H., Biswas, P., Cameron, M. C., Feeney, C., Encinas, G. A., Peeples-Lamirande, K., Cappelleri, J. C., et al. (2021) · JAAD International · doi:10.1016/j.jdin.2021.05.004 · Cited by 11
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kabashima, K., Oda, M., & Nagata, T. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.235 · Cited by 6
Gooderham, M., Weisman, J. D., Goldblum, O. M., Brinker, D. R., Issa, M., & Reich, K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.335 · Cited by 2
Lio, P., Soung, J., Cather, J., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.470 · Cited by 1
Cited by
Novel insights into atopic dermatitis
Schuler, C. F., Billi, A. C., Maverakis, E., Tsoi, L. C., & Gudjonsson, J. E. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.023 · Cited by 281
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
Kołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
Metadata
- Authors
- Chovatiya, R., & Paller, A. S.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 148
- Issue
- 4
- Pages
- 927-940
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3194970552
- Cited by
- 398
- References
- 80
- FWCI
- 38.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.